Cerus Corporation (CERS) Receives Analyst Rating

Cerus Corporation (CERS) : 5 analysts are covering Cerus Corporation (CERS) and their average rating on the stock is 1, which is read as a Strong Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.

Cerus Corporation (CERS) : 5 investment research analysts covering Cerus Corporation (CERS) have an average price target of $9.7 for the near short term. The highest target price given by the Brokerage Firm to the stock is $10 and the lowest target is $9 for the short term. Analysts expect the variance to be within $0.45 of the average price.


Cerus Corporation (NASDAQ:CERS): After opening at $6.07, the stock dipped to an intraday low of $5.98 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $6.18 and the buying power remained strong till the end. The stock closed at $6.13 for the day, a gain of 0.82% for the day session. The total traded volume was 504,666. The stocks close on the previous trading day was $6.08.

Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Companys INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries, including the United States, certain countries in Europe, The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.